Phase I and pharmacokinetics (PK) of combined erbB1 and erbB2 blockade with OSI-774 (erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with advanced solid tumors.

被引：0
|
作者：
Patnaik, A
Beeram, M
de Bono, JS
Mita, A
Chu, SC
Rowinsky, EK
Schwartz, G
O'Rourke, P
Takimoto, CH
Tolcher, AW
机构：
[1] CTRC, Inst Drug Dev, San Antonio, TX USA
[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
[3] Brooke Army Med Ctr, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：135S / 135S
页数：1
相关论文
共 37 条
  • [1] Phase I and pharmacokinetics (PK) of combined erbB1 and erbB2 blockade with OSI-774 (Erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with advanced solid tumors
    Beeram, M
    De Bono, JS
    Patnaik, A
    Mita, A
    Chu, SC
    Mita, MM
    O'Rourke, P
    Takimoto, CH
    Tolcher, AW
    Rowinsky, EK
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S95 - S95
  • [2] Impressive anti-tumor activity of combined erbB1 and erbB2 blockade: a phase I and pharmacokinetics (PK) study of OSI-774 (Erlotinib; E) and Trastuzumab (T) in combination with weekly Paclitaxel (P) in patients (pts) with advanced solid tumors
    Beeram, M.
    De Bono, J. S.
    Rowinsky, E. K.
    O'Rourke, P.
    Ricart, A.
    Hammond, L. A.
    Patnaik, A.
    Mita, M.
    Mita, A.
    Tolcher, A. W.
    EJC SUPPLEMENTS, 2006, 4 (12): : 183 - 183
  • [3] Impressive anti-tumor activity of combined erbB1 and erbB2 blockade with OSI-774 (eriotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with trastuzumab refractory breast cancer in a phase I pharmacokinetics (PK) study.
    Rodon, J.
    Beeram, M.
    de Bono, J. S.
    Patnaik, A.
    Mita, A.
    O'Rourke, P.
    Bruno, S.
    Papadapoulos, K.
    Takimoto, C.
    Tolcher, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S69
  • [4] Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors.
    Puzanov, I.
    Sarantopoulos, J.
    Gilbert, J.
    Mahalingam, D.
    Chap, L. I.
    Deng, H.
    Zhu, M.
    McCaffery, I.
    Friberg, G. R.
    Rosen, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors.
    Keilholz, U.
    Moiseyenko, V.
    Makhson, A.
    Semiglazov, V.
    Learoyd, M.
    Saunders, A.
    Stuart, M.
    Tjulandin, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors.
    Goel, Sanjay
    Moran, Teresa
    Coronado, Cinthya
    Ramirez, Santiago Viteri
    Chaudhary, Imran
    Ghalib, Mohammad Haroon
    Swami, Umang
    Hou, Yijuan
    Carcereny, Enric
    Alcantara, Jose
    Dios, Jorge Luis Iglesias
    De Miguel, Bernardo
    Buges, Cristina
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
    Papadopoulos, K. P.
    Chu, Q.
    Patnaik, A.
    Mita, M. M.
    Cooper, J.
    Van Maanen, R.
    Lopez-Lazaro, L.
    Lebedinsky, C.
    Rowinsky, E. K.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 86S - 86S
  • [8] A phase I study of oral uracil/ftorafur (UFT) plus leukovorin in combination with weekly paclitaxel (P) in patients (pts) with solid tumors.
    Mayer, F
    von Pawel, J
    Beck, J
    Schroeder, M
    Hartmann, JT
    Kanz, L
    Bokemeyer, C
    ANNALS OF ONCOLOGY, 2000, 11 : 136 - 136
  • [9] Final results of a phase I and pharmacokinetic (PK) study of OSI-7904L in combination with cisplatin (CDDP) in patients (pts) with advanced solid tumors.
    Ricart, AD
    Berlin, JD
    Syed, S
    Papadopoulos, K
    Drolet, D
    Quaratino-Baker, C
    Horan, J
    Chick, J
    Vermeulen, W
    Tolcher, AW
    Rowinsky, EK
    Rothenberg, ML
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9004S - 9005S
  • [10] Phase I clinical trial of pulse dose imatinib (Im) and weekly paclitaxel (P) in patients (pts) with advanced refractory solid tumors.
    Firozvi, KA
    Moore, D
    Min, FD
    Malik, S
    Egorin, M
    Hwang, JJ
    Ramzi, P
    Marshall, JL
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9117S - 9118S
1234